Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination |
| |
| Affiliation: | 1. Army College of Medical Sciences, India;2. B.J. Medical College and Civil Hospital, Ahmedabad, India;3. University of Pittsburgh Medical Center, Pittsburgh, PA, United States;4. Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States;5. West Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, United States |
| |
| Abstract: | As the news of approval of COVID-19 vaccination emerge, neurologists across the globe ponder upon whether to use immunotherapies in patients with Multiple Sclerosis (MS). This paper highlights the mechanism of various disease modifying therapies (DMTs) as well as the recently approved Pfizer and Moderna vaccines for COVID-19 as well as guidelines as introduced by National Multiple Sclerosis Society. As their mechanisms counteract each other at the molecular level, we believe further evidence and data might lay the foundation to formulate much needed recommendations for the usage of these medications while vaccinating MS patients on DMTs. |
| |
| Keywords: | COVID-19 Multiple Sclerosis COVID-19 vaccine Disease modifying therapies |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
